Cartesian Therapeutics (RNAC) Projected to Announce Earnings on Thursday

Cartesian Therapeutics (NASDAQ:RNAC) is anticipated to release its results before the market opens on Thursday, November 5th. Analysts expect Cartesian Therapeutics to announce earnings of ($1.02) per share and revenue of $0.16 million for the quarter.

Cartesian Therapeutics (NASDAQ:RNAC) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.46 earnings per share for the quarter, topping the consensus estimate of ($0.88) by $1.34. On average, analysts expect Cartesian Therapeutics to post ($3.15) EPS for the current fiscal year and ($4.14) EPS for the next fiscal year.

Cartesian Therapeutics Stock Up 3.6%

Cartesian Therapeutics stock opened at $6.69 on Thursday. The firm has a fifty day simple moving average of $7.89 and a two-hundred day simple moving average of $7.67. Cartesian Therapeutics has a twelve month low of $5.60 and a twelve month high of $11.00. The company has a market capitalization of $202.37 million, a PE ratio of -1.13 and a beta of 0.65.

Analyst Upgrades and Downgrades

RNAC has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Cartesian Therapeutics in a research report on Wednesday, September 30th. Wedbush reiterated an “outperform” rating and issued a $38.00 price objective on shares of Cartesian Therapeutics in a report on Tuesday, August 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cartesian Therapeutics in a research note on Wednesday, September 9th. Zacks Research raised shares of Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday, September 29th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cartesian Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $32.60.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc (NASDAQ: RNAC) is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s platform is designed to program a patient’s own immune cells with messenger RNA, enabling the development of cell therapies that are intended to provide targeted treatment without permanent genetic modification.

Cartesian’s lead product candidate is Descartes-08, an autologous CAR T-cell therapy that targets B-cell maturation antigen (BCMA).